Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioblastomas
(GBMs) are the most frequent and the most aggressive brain tumors, known for their chemo- and radio-resistance, making them often incurable. We also know that
SETMAR
is a protein involved in chromatin dynamics and genome plasticity, of which overexpression confers chemo- and radio-resistance to some tumors. The relationships between
SETMAR
and
GBM
have never been explored. To fill this gap, we define the
SETMAR
status of 44 resected tumors and of
GBM
derived cells, at both the mRNA and the protein levels. We identify a new, small SETMAR protein (so called
SETMAR
-1200), enriched in GBMs and
GBM
stem cells as compared to the regular enzyme (
SETMAR
-2100). We show that
SETMAR
-1200 is able to increase DNA repair by non-homologous end-joining, albeit with a lower efficiency than the regular SETMAR protein. Interestingly, the regular/small ratio of
SETMAR
in
GBM
cells changes depending on cell type, providing evidence that
SETMAR
expression is regulated by alternative splicing. We also demonstrate that
SETMAR
expression can be regulated by the use of an alternative ATG. In conclusion, various
SETMAR
proteins can be synthesized in human
GBM
that may each have specific biophysical and/or biochemical properties and characteristics. Among them, the small
SETMAR
may play a role in GBMs biogenesis. On this basis, we would like to consider
SETMAR
-1200 as a new potential therapeutic target to investigate, in addition to the regular SETMAR protein already considered by others.
...
PMID:SETMAR isoforms in glioblastoma: A matter of protein stability. 2803 63